Drug Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Drug Name RO5520985
Trade Name
Synonyms Vanucizumab|Ang-2-VEGF-A CrossMab|RG-7221|RO-5520985
Drug Descriptions

Vanucizumab (RO5520985) is a bispecific human antibody that binds to both Angiopoeitin-2 and VEGF-A, inhibiting tumor angiogenesis and metastasis in xenograft models (PMID: 24097868, PMID: 29217526, PMID: 32162804).

CAS Registry Number 1448221-05-3
NCIT ID C118578


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
Fluorouracil + Leucovorin + Oxaliplatin + RO5520985 Fluorouracil Leucovorin Oxaliplatin RO5520985 0 0
Fluorouracil + Leucovorin + RO5520985 Fluorouracil Leucovorin RO5520985 0 1
RO5520985 RO5520985 0 1
RO5520985 + Selicrelumab RO5520985 Selicrelumab 0 1

Additional content available in CKB BOOST